Skip to content
DataLookout
Menu

EXPLORENCT06945224

A ReaL World Study of DS-8201

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date changed from estimate of Jun 30, 2025 to Apr 1, 2026
    • Start date: Dec 1, 2024 to Apr 19, 2025
    • Eligibility criteria expanded, about 14 words
    • Study completion pushed from Jun 30, 2025 to Nov 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

PFS
Timeframe: Six months after the last patient was enrolled

Arms and interventions

Patients received DS-8201

HER2-positive and HER2-low breast cancer patients who received DS-8201 in the advanced stage

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer centerShanghai, China, China